Association of ABO(H) and i blood group system development with von Willebrand factor and Factor VIII plasma levels in children and adolescents

Transfusion

Volumn 50, Issue 7, 2010, Pages 1571-1580

  Klarmann, Dieter ^a,b,c   Eggert, Christine ^a,b,c   Geisen, Christof ^a,b,c   Becker, Sabine ^a,b,c   Seifried, Erhard ^a,b,c   Klingebiel, Thomas ^a,b,c   Kreuz, Wolfhart ^a,b,c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Medizinischer Dienst der Krankenversicherung in Hessen ^*  (Germany)

^c Institute of Transfusion Medicine and Immune Hematology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8C; BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; BLOOD GROUP H ANTIGEN; GLYCAN; VON WILLEBRAND FACTOR;

ADOLESCENCE; ADOLESCENT; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP I SYSTEM; BLOOD GROUP O; BLOOD LEVEL; CHILD; CHILDHOOD; COMPARATIVE STUDY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; INFANT; MALE; NORMAL HUMAN; PRESCHOOL CHILD; REFERENCE VALUE; SCHOOL CHILD;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HUMANS; I BLOOD-GROUP SYSTEM; INFANT; MALE; VON WILLEBRAND FACTOR;

EID: 77954325425     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02604.x     Document Type: Article

References (51)

1. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Powers P. Development of the human coagulation system in the full-term infant. Blood 1987 70 : 165 72.
2. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, Castle V, Powers P. Development of the human coagulation system in the healthy premature infant. Blood 1988 72 : 1651 7.
3. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992 80 : 1998 2005.
4. Flanders MM, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for seven common coagulation assays. Clin Chem 2005 51 : 1738 42.
5. Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM. Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr 2006 149 : 275 7.
6. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, De RL, Hamilton S, Ragg P, Robinson S, Auldist A, Crock C, Roy N, Rowlands S. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006 95 : 362 72.
7. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 69 : 1691 5.
8. Morelli VM, de Visser MC, van Tilburg NH, Vos HL, Eikenboom JC, Rosendaal FR, Bertina RM. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007 97 : 534 41.
9. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002 22 : 335 41.
10. Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol 2006 133 : 457 67.
11. Davies JA, Collins PW, Hathaway LS, Bowen DJ. C1584: effect on von Willebrand factor proteolysis and von Willebrand factor antigen levels. Acta Haematol 2009 121 : 98 101.
12. Denis CV, Christophe OD, Oortwijn BD, Lenting PJ. Clearance of von Willebrand factor. Thromb Haemost 2008 99 : 271 8.
13. Federici AB, Elder JH, De ML, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984 74 : 2049 55.
14. Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 2008 112 : 1713 9.
15. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 2006 46 : 1836 44.
16. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA. N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 2008 111 : 3042 9.
17. Pendu R, Christophe OD, Denis CV. Mouse models of von Willebrand disease. J Thromb Haemost 2009 7 Suppl 1 : 61 4.
18. Samor B, Michalski JC, Debray H, Mazurier C, Goudemand M, Van HH, Vliegenthart JF, Montreuil J. Primary structure of a new tetraantennary glycan of the N-acetyllactosaminic type isolated from human factor VIII/von Willebrand factor. Eur J Biochem 1986 158 : 295 8.
19. Issitt Peter D, Anstee David J. Applied blood group serology. 4th ed.
20. Klein HG, Anstee David J. Mollison's blood transfusion in clinical medicine. 7th ed.
21. dbRBC. Blood group antigen gene mutation database, 2009 cited 2010 Jan 4]. Available from: URL: http://www.ncbi.nlm.nih.gov/projects/gv/rbc/xslcgi. fcgi?cmd=bgmut/systems-info&system=i
22. Hakomori S. Blood group ABH and Ii antigens of human erythrocytes: chemistry, polymorphism, and their developmental change. Semin Hematol 1981 18 : 39 62.
23. NCCLS. How to define and determine reference intervals in the clinical laboratory; approved guideline. 2nd ed. NCCLS document C28-A2 (ISBN 1-56238-406-6).
24. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005 128 : 100 7.
25. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002 116 : 350 6.
26. O'Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res 2000 37 : 540 7.
27. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003 1 : 33 40.
28. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005 106 : 1988 91.
29. Millar CM, Brown SA. Oligosaccharide structures of von Willebrand factor and their potential role in von Willebrand disease. Blood Rev 2006 20 : 83 92.
30. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008 111 : 3540 5.
31. Sztukowska M, Gallinaro L, Cattini MG, Pontara E, Sartorello F, Daidone V, Padrini R, Pagnan A, Casonato A. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease. Br J Haematol 2008 143 : 107 14.
32. Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007 138 : 534 40.
33. Groot E, Fijnheer R, Sebastian SA, de Groot PG, Lenting PJ. The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission. J Thromb Haemost 2009 7 : 962 9.
34. Katz JA, Moake JL, McPherson PD, Weinstein MJ, Moise KJ, Carpenter RJ, Sala DJ. Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma. Blood 1989 73 : 1851 8.
35. Staropoli JF, Stowell CP, Tuncer HH, Marques MB. An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura. Vox Sang 2009 96 : 344 8.
36. Zuberi L, Yerasuri D, Kuriakose P. Effect of blood group on idiopathic thrombotic thrombocytopenic purpura. J Clin Apher 2009 24 : 131 3.
37. Zhou W, Tsai HM. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood 2009 113 : 929 35.
38. van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, van den Berg HM, Denis CV, Lenting PJ. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008 112 : 1704 12.
39. Terraube V, O'Donnell JS, Jenkins PV. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance. Haemophilia 2010 16 : 3 13.
40. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001 11 : 343 51.
41. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood 2009 113 : 5049 57.
42. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006 4 : 766 73.
43. Tosetto A, Rodeghiero F, Castaman G, Bernardi M, Bertoncello K, Goodeve A, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). J Thromb Haemost 2007 5 : 715 21.
44. James PD, Paterson AD, Notley C, Cameron C, Hegadorn C, Tinlin S, Brown C, O'Brien L, Leggo J, Lillicrap D. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006 4 : 783 92.
45. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007 109 : 145 54. (Pubitemid 46053055)
46. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006 96 : 630 41.
47. Collins PW, Cumming AM, Goodeve AC, Lillicrap D. Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia 2008 14 : 685 96.
48. Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003 101 : 2089 93.
49. Rodeghiero F, Kadir RA, Tosetto A, James PD. Relevance of quantitative assessment of bleeding in haemorrhagic disorders. Haemophilia 2008 14 Suppl 3 : 68 75.
50. Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009 7 : 1418 21.
51. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost 2008 6 : 62 9.